Skip to main content
Journal cover image

Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.

Publication ,  Journal Article
FUTURE II Study Group,
Published in: J Infect Dis
November 15, 2007

BACKGROUND: A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle (VLP) vaccine has been shown to be 95%-100% effective in preventing cervical and genital disease related to HPV-6, -11, -16, and -18 in 16-26-year-old women naive for HPV vaccine types. Because most women in the general population are sexually active, some will have already been infected with > or =1 HPV vaccine types at the time vaccination is offered. Here, we assessed whether such infected women are protected against disease caused by the remaining HPV vaccine types. METHODS: Two randomized, placebo-controlled trials of the quadrivalent (types 6, 11, 16, and 18) HPV vaccine enrolled 17,622 women without consideration of baseline HPV status. Among women infected with 1-3 HPV vaccine types at enrollment, efficacy against genital disease related to the HPV vaccine type or types for which subjects were naive was assessed. RESULTS: Vaccination was 100% effective (95% confidence interval [CI], 79%-100%) in preventing incident cervical intraepithelial neoplasia 2 or 3 or cervical adenocarcinoma in situ caused by the HPV type or types for which the women were negative at enrollment. Efficacy for preventing vulvar or vaginal HPV-related lesions was 94% (95% CI, 81%-99%). CONCLUSIONS: Among women positive for 1-3 HPV vaccine types before vaccination, the quadrivalent HPV vaccine protected against neoplasia caused by the remaining types. These results support vaccination of the general population without prescreening.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Infect Dis

DOI

ISSN

0022-1899

Publication Date

November 15, 2007

Volume

196

Issue

10

Start / End Page

1438 / 1446

Location

United States

Related Subject Headings

  • Uterine Cervical Neoplasms
  • Uterine Cervical Dysplasia
  • Treatment Outcome
  • Sexually Transmitted Diseases, Viral
  • Prospective Studies
  • Polymerase Chain Reaction
  • Papillomavirus Vaccines
  • Papillomavirus Infections
  • Papillomaviridae
  • Microbiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
FUTURE II Study Group, . (2007). Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis, 196(10), 1438–1446. https://doi.org/10.1086/522864
FUTURE II Study Group, Sathyamangla V Naga. “Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.J Infect Dis 196, no. 10 (November 15, 2007): 1438–46. https://doi.org/10.1086/522864.
FUTURE II Study Group, Sathyamangla V. Naga. “Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.J Infect Dis, vol. 196, no. 10, Nov. 2007, pp. 1438–46. Pubmed, doi:10.1086/522864.
Journal cover image

Published In

J Infect Dis

DOI

ISSN

0022-1899

Publication Date

November 15, 2007

Volume

196

Issue

10

Start / End Page

1438 / 1446

Location

United States

Related Subject Headings

  • Uterine Cervical Neoplasms
  • Uterine Cervical Dysplasia
  • Treatment Outcome
  • Sexually Transmitted Diseases, Viral
  • Prospective Studies
  • Polymerase Chain Reaction
  • Papillomavirus Vaccines
  • Papillomavirus Infections
  • Papillomaviridae
  • Microbiology